Suchergebnisse - "O3J8G9O825"

PubPharm (834)

1

Proof-of-concept studies with a computationally designed Mpro inhibitor as a synergistic combination regimen alternative to Paxlovid

enthalten in: Proceedings of the National Academy of Sciences of the United States of America | 2024

von Papini, C. | Ullah, I. | Ranjan, A. | +11

2

A combination of nirmatrelvir and ombitasvir boosts inhibition of SARS-CoV-2 replication

enthalten in: Antiviral research | 2024

von Moon, C. | Porges, E. | Roberts, A. | +1

3

Review : The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2024

von Meyerowitz, E. | Li, Y.

4

COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina

enthalten in: The Journal of antimicrobial chemotherapy | 2024

von Henderson, H. | Wohl, D. | Fischer, W. | +8

5

The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance

enthalten in: Antiviral research | 2024

von Schreiber, A. | Rodner, F. | Oberberg, N. | +5

6

Predictors of nirmatrelvir-ritonavir receipt among COVID-19 patients in a large US health system

enthalten in: Scientific reports | 2024

von Malden, D. | McLaughlin, J. | Hong, V. | +8

7

Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease

enthalten in: Virology journal | 2024

von Colaneri, M. | Scaglione, G. | Fassio, F. | +20

8

Physician characteristics associated with antiviral prescriptions for older adults with COVID-19 in Japan : an observational study

enthalten in: BMJ open | 2024

von Miyawaki, A. | Kitajima, K. | Iwata, A. | +2

9

Safety profile of nirmatrelvir-ritonavir : Evidence of adverse events due to drug-drug interactions

enthalten in: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria | 2024

von González-Gómez, �. | Caro-Teller, J. | González-Barrios, I. | +3

10

Translated article] Safety profile of nirmatrelvir-ritonavir : Evidence of adverse events due to DDIs

enthalten in: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria | 2024

von González-Gómez, �. | Caro-Teller, J. | González-Barrios, I. | +3

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[84]